Department of Family Practice & Community Health, Ajou University School of Medicine, San 5, Woncheon-dong, Yeongtong-gu, Suwon, Korea.
Chin Med J (Engl). 2012 Feb;125(4):569-73.
The association of emerging biomarkers such as high-sensitivity C-reactive protein (hs-CRP), homocysteine and fibrinogen with the risk of coronary artery disease (CAD) is still uncertain in Asian population including Koreans and little is known about the combined effect of biomarkers on the risk of CAD.
A total of 10 650 subjects (6538 men and 4112 women) were enrolled in this study. A 10-year CAD risk was calculated using Framingham risk score modified by the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) and levels of circulating hs-CRP, homocysteine and fibrinogen were measured using validated assays.
The 10-year CAD risk gradually augmented with increase in the circulating levels of hs-CRP, homocysteine and fibrinogen. For the highest quartile of hs-CRP, odds ratio (OR) of high-risk for CAD (10-year risk ≥ 20%) compared with the lowest quartile was 3.97 (95%CI: 2.51 - 6.29). For homocysteine and fibrinogen, ORs in the highest quartile compared to the lowest quartile were 5.10 (95%CI: 3.05 - 8.53, P < 0.001) and 1.46 (95%CI: 0.69 - 3.11, P = 0.325), respectively. OR of high-risk for CAD in both the highest quartile of hs-CRP and homocysteine was 9.05 (95%CI: 5.30 - 15.45) compared with the below median of hs-CRP and homocysteine.
The present study demonstrated that hs-CRP and homocysteine are well associated with the 10-year CAD risk estimated using NCEP ATP III in Koreans and combination of hs-CRP and homocysteine can have strong synergy in predicting the development of CAD.
在亚洲人群中,包括韩国人在内,新兴生物标志物(如高敏 C 反应蛋白[hs-CRP]、同型半胱氨酸和纤维蛋白原)与冠心病(CAD)风险的相关性仍不确定,关于这些生物标志物对 CAD 风险的综合影响知之甚少。
本研究共纳入 10650 例受试者(6538 例男性和 4112 例女性)。采用经国家胆固醇教育计划(NCEP)成人治疗专家组 III(ATP III)修正的 Framingham 风险评分计算 10 年 CAD 风险,使用验证后的检测方法测量循环 hs-CRP、同型半胱氨酸和纤维蛋白原水平。
随着 hs-CRP、同型半胱氨酸和纤维蛋白原循环水平的升高,10 年 CAD 风险逐渐升高。与最低四分位相比,hs-CRP 最高四分位的 CAD 高危(10 年风险≥20%)比值比(OR)为 3.97(95%CI:2.51-6.29)。对于同型半胱氨酸和纤维蛋白原,最高四分位与最低四分位相比,OR 分别为 5.10(95%CI:3.05-8.53,P<0.001)和 1.46(95%CI:0.69-3.11,P=0.325)。与 hs-CRP 和同型半胱氨酸中位数以下的患者相比,hs-CRP 和同型半胱氨酸均处于最高四分位的 CAD 高危 OR 为 9.05(95%CI:5.30-15.45)。
本研究表明,hs-CRP 和同型半胱氨酸与韩国人使用 NCEP ATP III 估计的 10 年 CAD 风险密切相关,hs-CRP 和同型半胱氨酸联合使用可在预测 CAD 发生方面具有很强的协同作用。